Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Completed	`NCT02197767` - Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis	Phase 2
Active, not recruiting	`NCT05546047` - A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients	Phase 4

See also

Status

Clinical Trial

Phase

Recruiting

NCT06065852 - National Registry of Rare Kidney Diseases

Completed

NCT02197767 - Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis

Phase 2

Active, not recruiting

NCT05546047 - A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

Phase 4

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT06295770
Study type	Interventional
Source	Mayo Clinic
Contact	Angela Reinke
Phone	507-266-1047
Email	Reinke.Angela@mayo.edu
Status	Recruiting
Phase	Phase 2
Start date	June 24, 2024
Completion date	May 2026

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms